Elevance Health price target raised to $431 from $412 at Bernstein

Bernstein raised the firm’s price target on Elevance Health (ELV) to $431 from $412 and keeps an Outperform rating on the shares. The firm sees a sector turnaround in the government managed care organization sector beginning in 2026, but expects to see bumps in the recovery. Bernstein believes all MCO sectors present attractive entry points, with Medicare Advantage likely to see the nearest term earnings improvements and Medicaid representing the most attractive valuations.